1-855-378-42281-855-378-4228
One of the outpatient rehab options for individuals in Charlestown who are struggling with opioid dependence and addiction is opioid maintenance therapy. Licensed facilities and doctors are certified to dispense specific medications to opioid dependent clients, many that are opioids themselves and are addiction. In low enough doses the client doesn't feel high and also does not have intense cravings and is not in opioid withdrawal. Methadone is the first drug tried for this reason, but there are a few more options currently to pick from.
Methadone is an opiate and can be taken at an out-patient medical center certified to dispense the drug, which is taken daily as a pill or liquid. The price of the drug is around $150 a month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But different from Methadone which is only be administered in well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The price monthly of buprenorphine is approximately three hundred dollars per month for the generic version of the medication. There is also a type of buprenorphine that contains the ingredient naloxone, that is a med that reverses the effects of opioids. A person taking this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced about $450 per month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other medications aforementioned it is an opioid blocker and is not an opiate. There is an option to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Treatment Programs In Charlestown, Click Here.
